CEO Raza Bokhari, co-founders Anthony Durkacz and Zeeshan Saeed, and other members of the company’s leadership team will represent the pharmaceutical cannabis research company at the CSE Media Centre in Toronto.
"We are immensely thrilled to ring the opening bell at the CSE to celebrate our accomplishment as the first CSE-listed company to dual-list onto a major US stock exchange," Bokhari said in a statement.
"Having raised a record $53 million in pre-listing capital and following our listing on the CSE in May 2018, we have continued to demonstrate a track record of success that is reflected in trading liquidity that tops 6 billion shares to date that is among the volume leaders on the CSE.”
The Toronto-based company started trading on the Nasdaq on January 9 and got to ring the opening bell in New York later that month.
"Today, we are among a select group of 12 Canadian-domiciled, cannabis-related companies that trade on a major US exchange,” Bokhari said. “I am very hopeful that sooner rather than later, we will be placed in a league of our own as we continue to demonstrate that the primary thrust of our business is to conduct US FDA-approved clinical trials on synthetic compounds with anti-inflammatory properties that target the endocannabinoid system of the human body."
Officials at the CSE were impressed at how far FSD has come.
"Entrepreneurs around the world have come to recognize the CSE as the ideal platform from which to access low-cost capital,” CSE CEO Richard Carleton said. “We celebrate one of our own in FSD Pharma as an emerging leader in the marketplace. What Raza and his leadership team have built serves as a roadmap for other entrepreneurs supported by CSE as their pre-eminent global listing venue."
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel